90 related articles for article (PubMed ID: 1337189)
1. Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy.
Gansevoort RT; Heeg JE; Vriesendorp R; de Zeeuw D; de Jong PE
Nephrol Dial Transplant; 1992; 7 Suppl 1():91-6. PubMed ID: 1337189
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.
Gansevoort RT; Heeg JE; Dikkeschei FD; de Zeeuw D; de Jong PE; Dullaart RP
Nephrol Dial Transplant; 1994; 9(3):244-50. PubMed ID: 8052429
[TBL] [Abstract][Full Text] [Related]
3. Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.
Rostoker G; Ben Maadi A; Remy P; Lang P; Lagrue G; Weil B
Nephrol Dial Transplant; 1995; 10(1):25-9. PubMed ID: 7724024
[TBL] [Abstract][Full Text] [Related]
4. Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy.
Hofstra JM; Deegens JK; Willems HL; Wetzels JF
Nephrol Dial Transplant; 2008 Aug; 23(8):2546-51. PubMed ID: 18308774
[TBL] [Abstract][Full Text] [Related]
5. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
[TBL] [Abstract][Full Text] [Related]
6. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone.
Rayner BL; Byrne MJ; van Zyl Smit R
Clin Nephrol; 1996 Oct; 46(4):219-24. PubMed ID: 8905205
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ; Wetzels JF
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
Lv J; Zhang H; Chen Y; Li G; Jiang L; Singh AK; Wang H
Am J Kidney Dis; 2009 Jan; 53(1):26-32. PubMed ID: 18930568
[TBL] [Abstract][Full Text] [Related]
9. Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.
Vogt L; de Zeeuw D; Woittiez AJ; Navis G
Nephrol Dial Transplant; 2009 Apr; 24(4):1182-9. PubMed ID: 19037084
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
[TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic.
Stiles KP; Abbott KC; Welch PG; Yuan CM
Clin Nephrol; 2001 Aug; 56(2):89-95. PubMed ID: 11522100
[TBL] [Abstract][Full Text] [Related]
12. [Efficiency of rituximab treatment for recurrence of membranous glomerulopathy after renal transplantation].
Wéclawiak H; Ribes D; Modesto A; Kamar N; Durand D; Rostaing L
Nephrol Ther; 2007 Apr; 3(2):65-8. PubMed ID: 17452303
[TBL] [Abstract][Full Text] [Related]
13. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
15. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage.
Lufft V; Kliem V; Hamkens A; Bleck JS; Eisenberger U; Petersen R; Ehlerding G; Maschek H; Pichlmayr R; Brunkhorst R
Clin Transplant; 1998 Oct; 12(5):409-15. PubMed ID: 9787950
[TBL] [Abstract][Full Text] [Related]
16. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
[TBL] [Abstract][Full Text] [Related]
17. [The late results of treating membranous glomerulonephritis].
Belovezhdov N; Robeva R; Dimitrova V
Vutr Boles; 1990; 29(3):53-60. PubMed ID: 2284800
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate.
du Buf-Vereijken PW; Branten AJ; Wetzels JF;
Nephrol Dial Transplant; 2004 May; 19(5):1142-8. PubMed ID: 14993502
[TBL] [Abstract][Full Text] [Related]
19. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
Sato A; Hayashi K; Saruta T
Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for idiopathic membranous nephropathy: who can benefit?
Ruggenenti P; Chiurchiu C; Abbate M; Perna A; Cravedi P; Bontempelli M; Remuzzi G
Clin J Am Soc Nephrol; 2006 Jul; 1(4):738-48. PubMed ID: 17699281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
